Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Selank peptide: does it work, is it legal, and what does it cost?

Anti-anxiety nasal peptide registered in Russia, with small randomized but unblinded trials against benzodiazepines; not FDA approved, nomination withdrawn.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

Quick answers

Quick answers about Selank
Does it work in people?Evidence: Human RCT evidence

At least one randomized human trial in PubMed. See the evidence

Is it legal?Regulatory: Nomination withdrawn

Not FDA approved and not on FDA's list of substances pharmacies may compound (the 503A bulks list), so a pharmacy has no federal basis to compound it. [5] [10] See legal status

What does it cost?No lawful compounded price: selank is off 503A Category 2 but is not on the 503A bulks list and was not among the peptides FDA presented to PCAC in July 2026. Insurance does not cover it. See cost by channel
Side effects?No systematic safety data from blinded trials. Nasal irritation with intranasal use. Fatigue or drowsiness reported anecdotally despite claims of no sedation. See side effects and interactions
Tested athlete?WADA: WADA status unclear

What is Selank?

Selank is a seven amino acid synthetic analog (modified version) of tuftsin, a natural immune signaling fragment, developed in Moscow and registered in Russia as nasal drops for anxiety and asthenia (chronic fatigue and weakness). Small Russian trials, two of them randomized, compared it with benzodiazepines (sedating anxiety drugs): one found an anxiolytic (anti-anxiety) effect similar to medazepam, and one found that adding selank to phenazepam brought earlier relief and fewer benzodiazepine side effects. These trials were unblinded, had no placebo group, came from the developer's network, and have not been independently replicated, and no blinded placebo controlled trial (where no one knows who got the real drug) has been published. Rodent studies suggest actions on GABA receptors (the brain's calming system), serotonin, and enkephalin breakdown. It has never been approved by FDA, was placed on the 503A Category 2 list (compounding ingredients flagged for significant safety risks) in 2023, is now listed by FDA as a withdrawn nomination (off Category 2 but not on the bulks list of ingredients pharmacies may use), and was not among the peptides FDA presented to the Pharmacy Compounding Advisory Committee (FDA's outside expert panel) in July 2026.

Selank is a synthetic heptapeptide analog of the immune tetrapeptide tuftsin (Thr-Lys-Pro-Arg) extended with Pro-Gly-Pro, a Russian anxiolytic peptide. It is also known as Thr-Lys-Pro-Arg-Pro-Gly-Pro, Tuftsin-Pro-Gly-Pro, Selank 0.15% nasal drops, N-acetyl Selank and NA-Selank amidate (unstudied analogs), Selank peptide, Selank nasal spray, Selank nasal drops.

How does it work?

Selank is built from tuftsin, a natural immune stimulating fragment of immunoglobulin G, with a C-terminal Pro-Gly-Pro added for stability. Proposed mechanisms from rodent and cell work include allosteric modulation of GABA-A receptors, inhibition of enkephalin degrading enzymes (raising endogenous opioid peptide levels), modulation of serotonin and brain derived neurotrophic factor expression, and changes in cytokine expression. A 2018 review summarizes these molecular findings; none has been confirmed in humans.

Key facts
ClusterCognitive and neuroprotective
RoutesIntranasal drops (Russian product and most sold forms); Subcutaneous injection (as sold, no published human data)
Conditions studiedCognitive decline and nootropic use; Anxiety disorders; Depression
Recordv4, reviewed, verified Sep 30, 2026

Selank benefits: what the evidence shows

Evidence: Human RCT evidenceGrade assigned per the methodology.

Two indexed randomized trials decide the grade. Zozulya 2008 (PMID 18454096, tagged by PubMed as a randomized controlled trial) compared selank (30 patients) with the benzodiazepine medazepam (32 patients) in generalized anxiety disorder and neurasthenia, using Hamilton, Zung, and CGI scales, and found similar anxiolytic effects. Medvedev 2015 (PMID 26356395) randomly assigned 70 patients with anxiety disorders to phenazepam alone (30) or selank plus phenazepam (40) for 14 days; the add-on group improved earlier and had fewer benzodiazepine side effects, and the random assignment is stated in the full text, not the PubMed abstract. Both trials were unblinded with an active comparator and no placebo, come from the developer's network, and have not been independently replicated, so the grade describes how the evidence was gathered, not how well selank works.

Indexed studies by evidence grade
Evidence typeIndexed studiesParticipants (human)
Human randomized trials2132
Human observational studies160
Animal studies1n/a
All indexed studies4192

Human evidence

Zozulya 2008: 62 patients with generalized anxiety disorder or neurasthenia received selank (30) or the benzodiazepine medazepam (32). Anxiolytic effects on psychometric scales (Hamilton, Zung, CGI) were similar, selank also showed antiasthenic and psychostimulant effects, and the serum half-life of leu-enkephalin, low at baseline, rose during selank treatment. PubMed tags it as a randomized controlled trial. Medvedev 2014: comparative study of selank and phenazepam in 60 patients with anxiety disorders, reporting pronounced anxiolytic and mild nootropic effects of selank; randomization is not stated in the abstract. Medvedev 2015: open, naturalistic, prospective study in which 70 patients were randomly assigned to phenazepam alone (30) or selank plus phenazepam (40) for 14 days; the add-on group reached the anxiolytic effect earlier and had fewer benzodiazepine side effects during treatment and after withdrawal. The random assignment is described in the full text, not the PubMed abstract. None was blinded or placebo controlled, all come from the developer's network, and none has been independently replicated.

Animal evidence

Rodent studies report reduced anxiety like behavior in elevated plus maze and open field tests, improved memory retention, and modulation of GABA-A receptor function and monoamine turnover. Vyunova et al. 2018 review the molecular pharmacology, including effects on GABAergic transmission and gene expression in brain regions.

Key studies

Indexed studies of Selank
StudyDesign and populationOutcomeGrade
Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia2008 PMID 18454096Randomized controlled trial (PubMed publication type) with an active comparator, medazepam; no placebo group; blinding not stated in the abstract; Russian languagen = 62 Patients with generalized anxiety disorder or neurasthenia: selank (30) or medazepam (32)Anxiolytic effects of selank and medazepam were similar on psychometric scales (Hamilton, Zung, CGI); selank also had antiasthenic and psychostimulant effects; serum leu-enkephalin half-life rose during selank treatmentEvidence: Human RCT evidence
A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders2014 PMID 25176261Comparative clinical study of selank and phenazepam; randomization not stated in the abstract; Russian languagen = 60 Patients with phobic-anxiety and somatoform disordersPronounced anxiolytic and mild nootropic effects of selank reported; the anxiolytic effect lasted a week after the last administration; improved quality of life; not placebo controlledEvidence: Human observational evidence
Optimization of the treatment of anxiety disorders with selank2015 PMID 26356395Open, naturalistic, prospective study with random assignment to two groups (randomization stated in the full text, not the PubMed abstract; PubMed publication type: randomized controlled trial); active control, no placebo; 14 days; Russian languagen = 70 Patients with anxiety-phobic, hypochondriac, and somatoform disorders: phenazepam alone (30) or selank plus phenazepam (40)Anxiolytic effect reached earlier in the add-on group; fewer phenazepam side effects (attention and memory impairment, asthenia, sedation) during treatment and after withdrawal; better quality of life; not blindedEvidence: Human RCT evidence
Peptide-based anxiolytics: the molecular aspects of heptapeptide selank biological activity2018 PMID 30255741Narrative review of molecular and animal pharmacologyRodent and cell studiesSummarizes GABA-A modulation, enkephalinase inhibition, monoamine effects, and gene expression changes underlying anxiolytic activity in animalsEvidence: Animal-only evidence

Conditions studied

Conditions with evidence for Selank
ConditionGradeNote
Cognitive decline and nootropic useEvidence: Human observational evidenceApproved in Russia for anxiety; its two randomized trials were unblinded, had no placebo group, and enrolled patients with anxiety disorders, so they do not raise the grade for cognition; one comparative anxiety study reported mild nootropic effects.
Anxiety disordersEvidence: Human RCT evidenceTwo randomized but unblinded Russian trials compared selank with benzodiazepines: the anxiolytic effect was similar to medazepam in 62 patients, and adding selank to phenazepam in 70 patients brought earlier improvement and fewer benzodiazepine side effects; no placebo group, from the developer's network, and not independently replicated; not FDA approved.
DepressionEvidence: Animal-only evidenceMechanism work in rodents covers GABA, monoamine, and stress pathways; human studies are in anxiety, not depression.

Is Selank legal in the United States?

Regulatory: Nomination withdrawnWADA: WADA status unclear

FDA and compounding status

Selank was placed on the FDA 503A Category 2 list (substances with significant safety risks) in 2023. The FDA Category 2 page current as of April 22, 2026 now lists selank acetate under bulk drug substances nominated but withdrawn, so it is no longer in Category 2, but it is not on the 503A bulks list and was not among the peptides FDA presented to the Pharmacy Compounding Advisory Committee on July 23 to 24, 2026. With no active nomination and no listing, a 503A pharmacy has no federal basis to compound it from bulk, and state boards cannot authorize what federal law does not. It is not an FDA approved drug and is not eligible for 503B outsourcing. It is a registered prescription drug in Russia.

WADA status

WADA status unclear. The current prohibited list does not name this compound explicitly and its class status is not settled. Athletes should ask their anti-doping organization before use.

Regulatory timeline

  1. FDA

    FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2

    FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.

  2. FDA

    FDA places a batch of nominated peptides in 503A Category 2

    In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.

Full tracker for Selank or the category-wide tracker.

Email me when Selank's status changes

Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.

What published studies of Selank used

Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.

Russian clinical studies used intranasal selank 0.15% solution at roughly 0.3 to 2.7 mg per day (2 to 3 drops per nostril, up to 3 times daily) for 10 to 14 days, according to Russian labeling and open label reports. No dose finding trial has been published in an indexed English language journal.

Routes reported

Routes of administration reported for Selank
#Route
1Intranasal drops (Russian product and most sold forms)
2Subcutaneous injection (as sold, no published human data)

Selank side effects

Side effects

Side effects reported for Selank
#Reported side effect
1No systematic safety data from blinded trials
2Nasal irritation with intranasal use
3Fatigue or drowsiness reported anecdotally despite claims of no sedation
4Long term safety unknown

Interactions

Interactions reported for Selank
#Interaction
1No formal human interaction studies exist
2Theoretical additive effects with benzodiazepines, alcohol, and other GABAergic drugs given proposed GABA-A modulation (not tested)
3Theoretical interaction with opioids via enkephalinase inhibition (not tested)

Contraindications

Contraindications for Selank
#Contraindication
1Russian labeling lists pregnancy, breastfeeding, and hypersensitivity
2Children (no indexed data)
3Competitive athletes should confirm status with their anti-doping organization

How do people access Selank legally?

Typical cost: No lawful compounded price: selank is off 503A Category 2 but is not on the 503A bulks list and was not among the peptides FDA presented to PCAC in July 2026. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.

Access options

  • Not available

    Selank is off Category 2 but not on the 503A bulks list, so a 503A pharmacy has no federal basis to compound it from bulk.

  • Not available

    Not available as an FDA approved product; registered prescription drug in Russia.

  • Not available

    Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.

Access paths are checked against public regulatory records. Products labeled research use only are never listed.

Compare Selank

What's actually offered, and what that means for you

FDA has found a compounding pharmacy offering selank anyway. [9]

Being offered does not change the legal status of selank. Selank is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [5] [10]

What FDA found

  • April 2020: FDA named selank among the bulk substances a state-licensed 503A pharmacy compounded outside section 503A. [9]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [10] [11] [12] [13] [14] [15]

What that means for you

  • A pharmacy that compounds selank is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [11] [12]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [15]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [16]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [17] [18]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [10]
  • Insurance rarely covers it, so you usually pay cash.
  • For tested athletes, WADA status is unclear; ask your anti-doping organization before any use. [7]

If you're going ahead anyway

These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound selank, with or without a prescription. [5]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [19] [20] [21]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [21] [22] [23]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [15] [24] [25] [26] [27] [28]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [15]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [19]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [23]
  • Pharmacy: Is this made for me on a prescription written in my name? [22]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [21] [23]
  • Prescriber: What is the legal basis for a pharmacy to compound selank? Is it FDA approved or on the 503A bulks list? [5] [15]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [23]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [16]

Frequently asked questions

What is selank?

Selank is a synthetic seven amino acid peptide built from tuftsin, a natural immune signaling fragment, with a Pro-Gly-Pro tail added for stability. It was developed in Moscow and is registered in Russia as nasal drops for anxiety. It is not FDA approved, is not on the 503A bulks list (ingredients pharmacies may use to compound drugs for individual patients), and was not among the peptides FDA presented to its advisory committee in July 2026, so there is no lawful US source. [1] [4] [5] [6]

Is selank legal in the United States?

It is not an FDA approved drug, but possessing it is not a crime. Selank was placed on FDA's 503A Category 2 list in 2023. FDA now lists it as a withdrawn nomination (off Category 2 but not on the 503A bulks list), and it was not among the peptides FDA presented to the committee in July 2026, so a 503A pharmacy has no federal basis to compound it from bulk. It is a prescription drug in Russia. [5] [6]

Selank benefits: does it work for anxiety?

Small Russian trials suggest it does, with caveats. A 2008 randomized trial in 62 patients with generalized anxiety disorder and neurasthenia found an anxiolytic effect similar to the benzodiazepine medazepam, and a 2015 trial that randomly assigned 70 patients found that adding selank to phenazepam brought earlier relief and fewer benzodiazepine side effects. Both were unblinded, had no placebo group, came from the developer's network, and have not been independently replicated, so the true effect size is unknown. PeptideAgent grades the evidence human RCT because randomized trials are indexed; the grade describes how the evidence was gathered, not how well selank works. [1] [3]

How does selank work?

The proposed mechanisms come from rodent and cell studies: modulation of GABA-A receptors, slower breakdown of enkephalins (the body's own opioid peptides), and changes in serotonin, BDNF, and immune gene expression. A 2008 clinical study linked its anti-anxiety effect to changes in enkephalin degrading activity in patients' blood. None of these mechanisms has been confirmed in controlled human research, and PeptideAgent found no indexed human pharmacokinetic study, so its half-life in people is unknown. [1] [4]

What are the side effects of selank?

No blinded safety trial exists. Nasal irritation is the most common complaint with drops. A 2015 trial reported that adding selank to phenazepam reduced the benzodiazepine's side effects, and anecdotal reports mention fatigue in some users. Long term safety has not been studied. [3]

How is selank taken?

As nasal drops, the form registered in Russia as a 0.15% solution and the route used in the published human studies. Injectable versions are sold but have no published human data. Selank is not an approved drug in the United States, so there is no US labeled dose. PeptideAgent does not give doses for unapproved peptides. [1] [3]

How much does selank cost?

There is no lawful compounded price: it is not on the 503A bulks list, and advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. [5] [8]

Is selank banned by WADA?

Unclear. Selank is not named on the WADA Prohibited List, and because it is an approved drug in Russia it does not automatically fall under section S0 for non-approved substances. Athletes should confirm with their anti-doping organization before use. [7]

Selank vs semax: which is better?

They target different things. Selank is a tuftsin analog studied for anxiety in small, unblinded Russian trials against benzodiazepines, two of them randomized; semax is an ACTH fragment studied for stroke recovery and cognition with rodent BDNF data. FDA presented semax to its advisory committee in July 2026; news reports said the committee voted to recommend listing it, but FDA's own briefing recommended against listing, and FDA has not posted the vote or minutes. Selank was not among the peptides FDA presented to the committee in July 2026. Neither has an independent blinded placebo controlled trial. [1] [3] [4] [6]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

From the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Zozulya AA et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova 2008PubMed 18454096, 2008
  2. [2]Medvedev VE et al. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova 2014PubMed 25176261, 2014
  3. [3]Medvedev VE et al. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova 2015PubMed 26356395, 2015
  4. [4]Vyunova TV et al. Peptide-based anxiolytics: the molecular aspects of heptapeptide selank biological activity. Protein Pept Lett 2018PubMed 30255741, 2018
  5. [5]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  6. [6]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  7. [7]WADA Prohibited ListWADA, 2026
  8. [8]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
  9. [9]FDA warning letter 594743, April 1, 2020, to a state-licensed 503A compounding pharmacy (FDA warning letters database)FDA, 2020
  10. [10]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2)FDA

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, September 30). Selank: evidence, legality, and access. https://peptideagent.ai/peptides/selank
HTML link
<a href="https://peptideagent.ai/peptides/selank">Selank: evidence, legality, and access</a>, PeptideAgent, updated September 30, 2026.